Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipid-lowering agents and myopathy.

Robert L Wortmann1

  • 1Department of Internal Medicine, The University of Oklahoma College of Medicine, Tulsa, 74135-2512, USA. robert-wortmann@ouhsc.edu

Current Opinion in Rheumatology
|November 1, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical features related to statin-associated muscle symptoms.

Muscle & nerve·2018
Same author

The causes of drug-induced muscle toxicity.

Current opinion in rheumatology·2014
Same author

Noninflammatory myopathies.

Rheumatic diseases clinics of North America·2013
Same author

Latest evidence on gout management: what the clinician needs to know.

Therapeutic advances in chronic disease·2013
Same author

Hyperuricemia and gout: new concepts in diagnosis and management.

Postgraduate medicine·2013
Same author

The molecular basis of skeletal muscle weakness in a mouse model of inflammatory myopathy.

Arthritis and rheumatism·2012

Lipid-lowering drugs can cause muscle problems, ranging from mild pain to severe rhabdomyolysis. Dosage, other medications, and individual metabolism influence the risk of statin-induced myopathy.

Area of Science:

  • Pharmacology
  • Clinical Toxicology
  • Muscle Physiology

Background:

  • Lipid-lowering agents are widely prescribed to manage hyperlipidemia.
  • Myopathy is a known adverse effect associated with these medications.
  • The spectrum of myopathy ranges from mild symptoms to life-threatening conditions like rhabdomyolysis.

Purpose of the Study:

  • To summarize the potential for myopathy caused by lipid-lowering agents.
  • To highlight the clinical spectrum and risk factors associated with drug-induced myopathy.
  • To discuss the speculative pathophysiology and contributing factors to myotoxicity.

Main Methods:

  • Literature review of adverse events associated with lipid-lowering therapies.
  • Analysis of clinical presentations and outcomes of myopathy.

Related Experiment Videos

  • Discussion of pharmacokinetic and pharmacodynamic factors influencing toxicity.

    • Main Results:

    • All available lipid-lowering agents carry a risk of myopathy.
    • Myopathy severity varies significantly, from asymptomatic creatine kinase elevations to severe rhabdomyolysis.
    • Significant myopathy is rare but poses a considerable problem due to widespread drug use.

    Conclusions:

    • Myopathy is a dose-related adverse effect of lipid-lowering drugs.
    • Factors such as total drug dosage, drug interactions, and individual metabolic profiles can influence myotoxicity.
    • Further research into the pathophysiology is needed to mitigate this risk.